Upload File

home - clinicaltrials.gov...protocol date: december 16, 2015 statistical analysis plan (sap) date:...

  • Home
  • Documents
  • Home - ClinicalTrials.gov...Protocol Date: December 16, 2015 Statistical Analysis Plan (SAP) Date: March 3, 2017 1.0 TITLE PAGE : Allergan study sc1401 A Randomized, Multicenter, Double-blind,
64

Upload: others

Post on 09-Feb-2021

1 views

Category:

Documents


0 download

Report

TRANSCRIPT

  •          

                  

  •    

       

       

       

       

                   

       

       

             

          

          

                

          

       

                      

       

       

       

     

     

  •    

           

               

           

          

       

       

       

         

     


Allergan Product Catalogue

CENA713DJP02 protocol ver3 - ClinicalTrials.gov · 2019. 5. 6. · [Exelon/Rivastigmine] Clinical Trial Protocol [CENA713DJP02] NCT02703636 [A 24-week, open-label, multicenter study

ATBILDĪGA SADARBĪBA - Allergan

Allergan FCA Complaint

This is Allergan Brochure_072016

Titlpage - ClinicalTrials.gov

Schema - ClinicalTrials.gov

Ghosal - ClinicalTrials.gov

NCT03054870 - clinicaltrials.gov

BGB-3111-206 (NCT03206970) - ClinicalTrials.gov · 2018. 9. 6. · BGB-3111-206 (NCT03206970)A Single-Arm, Open-Label, Multicenter Phas e 2 Study to Evaluate Efficacy and Safety of

REP0114 - clinicaltrials.gov

Pembrolizumab Versus Investigator’s Choice Single-Agent ......• KEYNOTE-181 (ClinicalTrials.gov, NCT02564263) is an open-label, randomized, multicenter, phase 3 study designed

BGB-3111-206 (NCT03206970) - ClinicalTrials.gov · 2020. 4. 1. · BGB-3111-206 (NCT03206970)A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of

NCT03166618 Study ID: VOLUMA-007 Title: A multicenter, single … · 2018. 7. 17. · Approval Date: 01-Mar-2017 Allergan Confidential JUVÉDERM VOLUMA ® XC Protocol VOLUMA-007 Amendment

Amendment - ClinicalTrials.gov

PRADO - ClinicalTrials.gov

Allergan Biostatistics Analysis Plan Clinical Study Report€¦ · Allergan Biostatistics Analysis Plan – Clinical Study Report Study ID: CMO-US-GI-0429 Study Title: A Phase 4 Multicenter,

Statistical Analysis Plan - ClinicalTrials.gov · 2018. 8. 6. · RUC SAP 08Nov2017.docx Statistical Analysis Plan jCyte, Inc. Protocol JC-01 A Prospective, Multicenter, Open-Label,

PARTNERSTVO SA INTEGRITETOM - Allergan

Allergan Lawsuit

PROTOCOL SYNOPSIS - ClinicalTrials.gov · This is a Phase II/III randomized, open-label, multicenter study to compare the efficacy and safety of first line single-agent AZD3759 vs

TM - Allergan

Study Protocol A multicenter ... - ClinicalTrials.gov

Statistical Analysis Plan - ClinicalTrials.gov · 2018-03-21 · Statistical Analysis Plan . Protocol Title: Multicenter, Safety and Efficacy, ... receiving active treatment in both

GILEAU - ClinicalTrials.gov

Bill Ackman Allergan Presentation

ALLERGAN PARTNER PRIVILEGES'. PARTNER ALLERGAN … · 2017. 6. 13. · allergan partner privileges'. partner allergan partner privileges' program 20/2 recognizing your ongoing commitment

EWOLUTION - ClinicalTrials.gov

Study ID CMO US GI - ClinicalTrials.gov · 2019-01-22 · NCT02959983 Study ID: CMO‐US‐GI‐0429 Title: A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo‐Controlled,

Allergan v. Sandoz

MULTICENTER - mbc.pe

NAXIVA - ClinicalTrials.gov

Implantes Allergan

Ripple-AT Study: A multicenter and randomized study ... · Web viewStudy design The Ripple-AT study (clinicaltrials.gov ID: NCT02451995) was a multi-centre, prospective, and randomized

MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO … · bo . Allergan C Setipipran t This SA P treatmen t Finasteri group w i onfidential Tablets is based on arms – Seti de 1 mg QD